fenofibrate capsule
unit dose services - fenofibrate (unii: u202363uos) (fenofibrate - unii:u202363uos) - fenofibrate 134 mg
fenofibrate tablet film coated
remedyrepack inc. - fenofibrate (unii: u202363uos) (fenofibric acid - unii:bgf9mn2hu1) - fenofibrate 160 mg
fenofibrate capsule
st marys medical park pharmacy - fenofibrate (unii: u202363uos) (fenofibric acid - unii:bgf9mn2hu1) - fenofibrate 67 mg
fenofibrate tablet film coated
st marys medical park pharmacy - fenofibrate (unii: u202363uos) (fenofibrate - unii:u202363uos) - fenofibrate 160 mg
fenofibrate tablet film coated
lake erie medical & surgical supply dba quality care products llc - fenofibrate (unii: u202363uos) (fenofibrate - unii:u202363uos) - fenofibrate 160 mg
fenofibrate tablet
avera mckennan hospital - fenofibrate (unii: u202363uos) (fenofibric acid - unii:bgf9mn2hu1) - fenofibrate 48 mg
fenofibrate tablet
aphena pharma solutions - tennessee, llc - fenofibrate (unii: u202363uos) (fenofibric acid - unii:bgf9mn2hu1) - fenofibrate 48 mg
fenofibrate capsule
alvogen inc. - fenofibrate (unii: u202363uos) (fenofibric acid - unii:bgf9mn2hu1) - fenofibrate 67 mg
fenofibrate tablet
unit dose services - fenofibrate (unii: u202363uos) (fenofibric acid - unii:bgf9mn2hu1) - fenofibrate 145 mg
fenofibrate tablet
northwind pharmaceuticals - fenofibrate (unii: u202363uos) (fenofibric acid - unii:bgf9mn2hu1) - fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (ldl-c), total cholesterol (total-c), triglycerides and apolipoprotein b (apo b), and to increase high-density lipoprotein cholesterol (hdl-c) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. fenofibrate tablets are also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dl) may increase the risk of developing pancreatitis. the effect of fenofibrate therapy on reducing this risk has not been adequately studied. fenofibrate at a dose equivalent to 160 mg of fenofibrate tablets was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 d